Form 8.3 - Horizon Therapeutics plc

LONDON--(BUSINESS WIRE)-- 

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	IE00BQPVQZ61
Date of dealing	14^th April 2023

2. INTERESTS AND SHORT POSITIONS

a. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	4,306,664 (1.883%)		24,037 (0.011%)
(2) Derivatives (other than options)	-		-
(3) Options and agreements to purchase/sell	379,900 (0.166%)		1,252,600 (0.548%)
Total	4,686,564 (2.041%)		1,276,637 (0.558%)

b. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

1. DEALINGS (Note 4)

a. Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (USD) (Note 5)
Sale	45	111.98
Sale	10,000	112.00
Sale	767	112.02
Sale	300	112.04
Sale	285	112.07
Sale	300	112.03
Sale	300	112.05
Sale	8,048	112.06
Sale	117	111.69
Sale	1	111.73
Sale	2	111.66
Sale	7	111.89
Sale	22	111.63
Sale	1,199	111.76
Sale	479	111.70
Sale	79	111.03
Sale	1,682	111.65
Sale	23	111.80
Sale	54	111.21
Sale	300	111.79
Sale	61	111.04
Sale	1	111.75
Sale	10	111.92
Sale	349	111.94
Sale	260	111.71
Sale	350	111.68
Sale	103	111.59
Sale	1,400	111.60
Sale	40	111.58
Sale	100	111.74
Sale	1,282	111.72
Sale	39	111.64
Sale	17	111.57
Sale	107	111.69
Sale	100	111.66
Sale	41	111.76
Sale	101	111.99
Sale	400	111.96
Sale	214	111.97
Sale	2	111.78
Sale	95	112.01
Sale	101	112.02
Sale	104	111.75
Sale	100	111.85
Sale	415	111.94
Sale	100	111.93
Sale	40	111.68
Sale	34	111.67
Purchase	1,913	111.60
Sale	100	111.74
Purchase	360	111.89
Sale	60	111.98
Sale	100	111.99
Sale	20	111.97
Purchase	121	112.02
Sale	20	112.02
Purchase	100	111.88
Purchase	99	112.04
Purchase	170	111.93
Sale	120	112.03
Purchase	320	111.60
Sale	647	111.60
Sale	20	111.62
Purchase	37	111.69
Sale	613	111.69
Sale	200	111.73
Sale	6,586	111.66
Sale	918	111.89
Purchase	2,250	111.63
Sale	145	111.63
Purchase	300	111.31
Purchase	1,000	111.76
Sale	566	111.76
Sale	4	111.70
Purchase	800	111.98
Sale	1,104	111.98
Purchase	1,740	111.18
Purchase	3,184	111.06
Purchase	100	111.03
Purchase	100	111.40
Purchase	900	111.20
Purchase	100	111.65
Sale	558	111.65
Purchase	1,282	111.17
Purchase	11,901	111.99
Sale	1,484	111.99
Purchase	1,430	111.24
Purchase	1,266	111.46
Purchase	509	111.22
Purchase	1,200	111.37
Purchase	14,013	112.00
Sale	6,928	112.00
Purchase	7,796	111.96
Sale	3,651	111.96
Purchase	118	111.82
Sale	470	111.82
Purchase	350	111.09
Purchase	237	111.14
Purchase	526	111.26
Sale	12	111.56
Purchase	15,918	111.97
Sale	3,707	111.97
Purchase	990	111.80
Sale	295	111.80
Purchase	100	111.77
Sale	712	111.77
Purchase	1,200	111.00
Purchase	843	111.10
Purchase	2	111.78
Sale	672	111.78
Purchase	22	111.87
Sale	200	111.87
Purchase	7,412	112.01
Sale	2,397	112.01
Purchase	259	112.02
Sale	1,520	112.02
Purchase	4,790	111.91
Sale	2,808	111.91
Purchase	849	111.34
Purchase	1,001	111.61
Purchase	2,080	111.15
Purchase	400	111.13
Sale	1,200	111.79
Sale	808	111.84
Purchase	600	111.35
Sale	3,062	111.88
Sale	300	111.75
Purchase	17,701	111.95
Sale	100	111.95
Purchase	3,677	111.92
Sale	624	111.92
Purchase	1,200	111.81
Sale	602	111.81
Purchase	2,854	111.90
Sale	402	111.90
Sale	1,106	111.85
Purchase	10,845	111.94
Sale	100	111.94
Purchase	183	112.04
Sale	4,046	112.04
Purchase	9,693	111.93
Sale	819	111.93
Purchase	500	112.10
Sale	2,041	112.10
Purchase	100	111.71
Sale	54	111.71
Sale	593	112.07
Purchase	1,351	112.03
Sale	16,034	112.03
Purchase	100	112.05
Sale	9,830	112.05
Purchase	140	111.68
Sale	541	111.68
Sale	433	111.86
Sale	6,894	111.67
Sale	200	112.09
Purchase	300	111.83
Purchase	350	111.59
Sale	302	111.59
Purchase	700	111.60
Sale	111	111.58
Sale	900	112.06
Sale	104	111.74
Purchase	100	112.16
Sale	307	111.72
Sale	3,593	111.64
Sale	200	112.11
Sale	100	112.08

b. Derivatives transactions (other than options transactions)

Product name, e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (USD) (Note 5)

c. Options transactions in respect of existing relevant securities

i. Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price (USD)	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)
Put Option	Purchasing	50,000	110.00	American	5/19/2023

ii. Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

d. Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure	17^th April 2023
Contact name	Sirina Kumar
Telephone number	[phone]
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making disclosure:	Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit (USD)	Type e.g. American, European etc.	Expiry date
IE00BQPVQZ61	Put Option	Purchased	1,100	90.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	11,500	110.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Written	262,400	115.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	42,500	120.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	55,200	110.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	2,900	80.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	300	80.00	American	1/17/2025
IE00BQPVQZ61	Put Option	Purchased	300	90.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	1,200	110.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	201,200	115.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Written	221,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	254,200	100.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	3,600	105.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	10,900	105.00	American	7/21/2023
IE00BQPVQZ61	Put Option	Purchased	5,200	105.00	American	4/21/2023
IE00BQPVQZ61	Call Option	Written	100,000	115.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Written	103,400	85.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	155,000	100.00	American	6/16/2023
IE00BQPVQZ61	Call Option	Purchased	300	110.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	300	110.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	200,000	100.00	American	8/18/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET

Sequence Number: 1081722

Time of Receipt (offset from UTC): 20230417T142815+0100